Strategy & Approach

Ms. Bakker is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Ms. Bakker was a Managing Director of Pequot Ventures, where she founded the life sciences investment practice. Prior to Pequot, she was Director, Strategic Planning and Director, Operations of Waste Management International, and a sell-side equity analyst with Banque Paribas. Ms. Bakker began her career as an investment banker in the corporate finance department at PaineWebber. She currently serves on the boards of Bolt Medical (acquired by Boston Scientific), Ceribell (CBLL), Endogenex, Nalu Medical, RxSight (RXST), and Sydnexis. Selected prior board memberships include Ablation Frontiers (acquired by Medtronic), Alphaeon, AqueSys (acquired by Allergan), Axonics Modulation Technologies (AXNX), CryoVascular Systems (acquired by Boston Scientific), Eargo (EAR), Embolic Protection (acquired by Boston Scientific), Enteric Medical (acquired by Boston Scientific), eyeonics (acquired by Bausch+Lomb), Genyx Medical (acquired by C.R. Bard), Insulet (PODD), Precision Dermatology (acquired by Valeant Pharmaceuticals), Sadra Medical (acquired by Boston Scientific), and Venus Concept (VERO). Ms. Bakker holds an MPA from the Harvard Kennedy School and a BSc from the College of Agriculture and Life Sciences (”CALS”) at Cornell University, where she serves on the Board of Trustees.
—
Focus Areas: Medical Technology, Health Solutions
Location: Boston

Mr. Bikoff is a Managing Director at Longitude Capital. Prior to joining Longitude Capital in 2016, Mr. Bikoff held a series of strategy, finance, and operating roles at Cardinal Health. While at Cardinal Health, he worked to deploy over $6 billion of capital through M&A and minority investments. Most recently, Mr. Bikoff was the Director of North America Marketing for the Cordis cardiovascular franchise. Mr. Bikoff currently serves on the boards of Kestra Medical and Polares Medical, and is a board observer at Bolt Medical. He previously served as a board observer at Amphora (acquired), Ceribell (CBLL), Eargo (EAR), Endogenex, LimFlow (acquired by Inari Medical), Nalu Medical, and RxSight (RXST), and was also actively involved in Longitude Capital’s investment in Axonics Modulation Technologies (AXNX) and PROCEPT BioRobotics (PRCT). Mr. Bikoff began his career in Deloitte Consulting’s Life Sciences Strategy practice and holds a BSE in Biomedical Engineering from Duke University.
—
Focus Areas: Medical Technology
Location: Menlo Park

Mr. Enright is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Enright was a Managing Director of Pequot Ventures, where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund and he began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis (VLTS), Hoffman – La Roche, and Novartis. Mr. Enright currently serves on the boards of BioAge Labs (BIOA), CuraSen Therapeutics, Endeavor Biomedicines, Epirium Bio, Jazz Pharmaceuticals (JAZZ), Opna Bio, Orbus Therapeutics, Vera Therapeutics (VERA), Veradermics, and Zenas BioPharma (ZBIO). Selected prior board memberships include Aimmune (AIMT, acquired by Nestlé), Codexis (CDXS), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Horizon Pharmaceuticals (HZNP, acquired by Amgen), InfaCare Pharmaceutical (acquired by Mallinckrodt), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Lundbeck), Sequenom (SQNM, acquired by LabCorp), Rivus Pharmaceuticals, Threshold Pharmaceuticals (THLD), Vaxcyte (PCVX), as well as the National Venture Capital Association (NVCA). Mr. Enright holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BS in Biological Sciences from Stanford University.
—
Focus Areas: Biotechnology, Health Solutions
Location: Menlo Park

Ms. Helms is a Managing Director and the Chief Financial Officer at Longitude Capital. Ms. Helms is responsible for the financial reporting of the Firm’s investment funds, as well as the day-to-day management of Firm-wide finance, tax, human resources, IT, and administration. In addition, Ms. Helms supports the Firm’s regulatory compliance program and works closely on legal, investor relations, and other operational matters. Ms. Helms served as the Firm’s Chief Compliance Officer from 2014 to September 2021. Prior to joining Longitude Capital in 2008, Ms. Helms was the Controller at Sierra Ventures, a venture capital firm focused on technology. Prior to Sierra Ventures, Ms. Helms was an Accounting Manager at NetManage, a publicly-traded software company, and was a Senior Auditor with Arthur Andersen LLP. Ms. Helms is a licensed CPA (inactive) and graduated cum laude with a BS in Business Administration (Accounting) from San Jose State University.
—
Focus Areas: Finance, Operations, Compliance
Location: Menlo Park

Dr. Liu is a Managing Director at Longitude Capital. Prior to joining Longitude Capital in 2018, Dr. Liu was an Engagement Manager in the pharmaceuticals and medical products practice of McKinsey & Company. Dr. Liu currently serves on the boards of Alentis Therapeutics, CG Oncology (CGON), Helicore Biopharma, and Lassen Therapeutics. Dr. Liu also currently serves as a board observer at Quanta Therapeutics. He previously served as a board observer at Dascena, Endeavor Biomedicines, Inflazome (acquired by Roche), Rivus Pharmaceuticals, Tourmaline Bio (TRML; formerly known as Talaris Therapeutics (TALS)), Vera Therapeutics (VERA), and Zenas Biopharma (ZBIO) and was also actively involved in Longitude Capital’s investment in Strongbridge Biopharma (SBBP; acquired by Xeris Biopharma). Dr. Liu holds an MD from Stanford School of Medicine and a BS in Biomedical Engineering from The Johns Hopkins University.
—
Focus Areas: Biotechnology
Location: Menlo Park

Mr. Young is a Managing Director of Longitude Capital. Prior to joining Longitude Capital in 2022, Mr. Young was the Chief Operating Officer and Chief Financial Officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina (ILMN) for $8 billion in 2021. From 2013 to 2019, Mr. Young held positions of increasing responsibility at Jazz Pharmaceuticals (JAZZ), a Longitude portfolio company, most recently as Executive Vice President and Chief Financial Officer. Prior to Jazz Pharmaceuticals, Mr. Young was an investment banker for nearly 20 years at Barclays Capital, Citigroup, Lehman Brothers, and Merrill Lynch, where he advised and led financings for hundreds of emerging and established life science companies. Additionally, Mr. Young served on the board of PRA Health Sciences (PRAH) until its acquisition by ICON plc for $12 billion in 2021, and currently serves as Lead Independent Director and Chairman of the Audit Committee of CytomX Therapeutics (CTMX). Mr. Young currently serves on the boards of AllinBio, Alpha-9 Oncology, and OrsoBio. He also led Longitude Capital’s investment in Aviceda Therapeutics and Mirum Pharmaceuticals (MIRM). Mr. Young holds an MBA and a BS in Economics from the Wharton School of the University of Pennsylvania.
—
Focus Areas: Biotechnology
Location: Menlo Park

Mr. Advani is a Senior Associate at Longitude Capital. Prior to joining Longitude Capital in 2024, Mr. Advani was an Investment Banking Analyst at Cowen, where he covered medical technology. He also was a Private Equity Analyst at Montage Partners prior to Cowen. Mr. Advani holds a BS in Accounting and a BS in Finance from the Arizona State University W. P. Carey School of Business.
—
Focus Areas: Medical Technology
Location: Menlo Park

Ms. Chen is a Senior Associate at Longitude Capital. Prior to joining Longitude Capital in 2024, Ms. Chen was an Investment Banking Analyst at Morgan Stanley in the Healthcare group, where she focused on the biopharmaceutical sector. Ms. Chen holds a MS in Biology and a BS in Human Biology with a minor in Management Science and Engineering from Stanford University.
—
Focus Areas: Biotechnology
Location: Boston

Dr. Ely is a Principal at Longitude Capital. Prior to joining Longitude Capital full-time in 2022, Dr. Ely was a Longitude Research Fellow. Dr. Ely’s work has been published in several leading journals, including Nature Biotechnology, Cancer Cell, and Nature Cancer. Dr. Ely serves as a board observer at Alentis Therapeutics, Alpha-9 Oncology, Helicore Bioventures, and Opna Bio. Dr. Ely earned a PhD in Biology from the Massachusetts Institute of Technology, where he specialized in gene editing and cancer immunology, and a BA in Molecular and Cellular Biology from Vanderbilt University. — Focus Areas: Biotechnology Location: Boston

Mr. Galletti is a Venture Partner and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Galletti was a Senior Vice President of Pequot Ventures, where he worked in the life sciences practice. Prior to Pequot Ventures, Mr. Galletti worked at Amerindo Investment Advisors, Vector Fund Management, and the Global Healthcare Investment Banking Group at J.P. Morgan & Co. Mr. Galletti began his career in the life sciences industry at APM, a management consultancy dedicated to improving operations performance within the patient care and procedural units of large acute-care hospitals. Mr. Galletti currently serves on the board of Murj. Selected prior board memberships include Amphora Medical (acquired), Aptus Endosystems (acquired by Medtronic), and Twelve (acquired by Medtronic), and he has also been involved with prior investments in Ablation Frontiers (acquired by Medtronic), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Lundbeck), Sadra Medical (acquired by Boston Scientific), and Threshold Pharmaceuticals (THLD). Mr. Galletti currently serves on the Healthcare at Kellogg Advisory Council at Northwestern University and on the HSBC Life Science Advisory Group. He previously served on advisory boards for the Innovation and New Ventures Office at Northwestern University and the Life Sciences Advisory Board of Silicon Valley Bank. Mr. Galletti holds an MBA in Finance and Health Services Management from the Kellogg School of Management at Northwestern University and a BA from Princeton University.
—
Focus Areas: Health Solutions
Location: Menlo Park

Dr. Gong is a Senior Associate at Longitude Capital. Prior to joining Longitude Capital in 2026, Dr. Gong consulted for Longitude Capital and completed fellowships at Compound and Divergence Labs. Dr. Gong’s work has been published in leading journals including Nature, Nature Genetics, and Cancer Cell, and has been supported by the National Science Foundation Graduate Research Fellowship. Dr. Gong earned a PhD from the Health Sciences and Technology program at Massachusetts Institute of Technology and Harvard Medical School, where he studied RAS inhibition and treatment resistance in pancreatic cancer. He completed a BS in Biomedical Engineering and Applied Math and Statistics from Johns Hopkins University.
—
Focus Areas: Biotechnology
Location: Boston

Dr. Guo is a Vice President at Longitude Capital. Prior to joining Longitude Capital in 2025, Dr. Guo completed fellowships with several healthcare and life sciences investment firms, including Foresite Capital, Aditum Bio, and Insight Partners. Dr. Guo’s work has been published in leading journals, including Nature, Nature Genetics, Nature Biotechnology, and The Lancet Oncology. Dr. Guo completed a PhD in Biological and Biomedical Sciences from Harvard Medical School, an MD from University of California, San Francisco, School of Medicine, and a BA in Biological Sciences from Cornell University.
—
Focus Areas: Biotechnology
Location: Menlo Park

Dr. Lim is a Senior Analyst focusing on public equities at Longitude Capital. Prior to joining Longitude Capital in 2024, Dr. Lim was an Analyst at Deep Track Capital, Lynx1,Walleye Capital, and Columbia Threadneedle, where he focused on biotechnology long/short public equities. Prior to that, Dr. Lim was an Investment Banking Vice President at Jefferies, where he covered healthcare companies. Dr. Lim holds a PhD in Neurobiology from California Institute of Technology, and an MS in Cancer Immunology and a BS in Molecular Biology from the University of California, San Diego.
—
Focus Areas: Biotechnology
Location: Menlo Park

Dr. Qi is a Venture Partner at Longitude Capital. Prior to beginning his work with Longitude Capital in 2025, Dr. Qi was a co-founding Investment Analyst at Seven Fleet Capital and an Investment Analyst at Walleye Capital, where he covered publicly listed pharmaceutical and biotechnology companies. Prior to that, Dr. Qi served in a variety of roles at the U.S. Food and Drug Administration, Hatteras Venture Partners, and Simulations Plus (SLP). Dr. Qi holds a PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill.
—
Focus Areas: Biotechnology
Location: Menlo Park

Dr. Vanhove is a Venture Partner at Longitude Capital. Dr. Vanhove has more than 25 years of clinical drug development and medical affairs experience across small and large biopharmaceutical companies. Prior to joining Longitude Capital in 2023, Dr. Vanhove most recently served as Chief Medical Officer of Surrozen (SRZN), a biotechnology company focused on discovering and developing novel regenerative medicines. Prior to Surrozen, Dr. Vanhove served as Vice President, Medical Affairs and, subsequently, Vice President of Search and Evaluation at Jazz Pharmaceuticals (JAZZ), a Longitude portfolio company. Prior to Jazz Pharmaceuticals, she served as Vice President, Medical Affairs at Depomed, Vice President, Clinical Development at NeurogesX, and a Medical Director at XOMA. She began her career as a Medical Director at Abbott Laboratories. Dr. Vanhove currently serves as a board observer at Epirium Bio and OrsoBio. Dr. Vanhove holds an MD and a PhD in Pharmacology from the Catholic University in Leuven, Belgium. She completed a fellowship in clinical pharmacology at Stanford University and holds an MBA from St. Mary’s College. Dr. Vanhove has authored, or co-authored, dozens of peer-reviewed articles, and is an inventor of numerous patents.
—
Focus Areas: Biotechnology
Location: Menlo Park

Ms. Cabreros is the Director of Operations & Facilities at Longitude Capital and is a member of the Finance team. Prior to joining Longitude Capital in 2017, Ms. Cabreros was a Tax Controller at Northgate Capital. She started her career with PricewaterhouseCoopers LLP, as a Senior Tax Accountant in the Venture Capital Group, which led to a finance position at ONSET Ventures, an early-stage venture capital investment firm focused on the information and medical technology sectors. During her tenure at ONSET, Ms. Cabreros was a Senior Accountant, Accounting Manager, and Assistant Controller. Ms. Cabreros holds a BA in Economics with an emphasis in Accounting from the University of California, Santa Cruz.
—
Location: Menlo Park

Ms. Caruso Wilson is a Compliance and Legal Manager at Longitude Capital. Prior to joining Longitude Capital in 2022, Ms. Caruso Wilson was a Compliance Consultant at ACA Global (formerly known as ACA Compliance), where she advised SEC-registered investment advisers on U.S. federal securities laws and helped develop and administer regulatory compliance programs for her clients. Ms. Caruso Wilson received her JD from the University of San Francisco School of Law and holds a BA in Political Science with a double minor in Criminology and Italian Language and Culture Studies from Marquette University. — Focus Areas: Legal, Compliance Location: Menlo Park

Ms. Holman is a Controller at Longitude Capital. Prior to joining Longitude Capital in 2013, Ms. Holman was an Audit Associate with Moss Adams LLP and PricewaterhouseCoopers LLP, where she served technology and life sciences companies, as well as venture capital firms. Ms. Holman holds a BS in Microbiology from San Jose State University and a Certificate of Advanced Accounting Proficiency from Santa Clara University.
—
Location: Menlo Park

Ms. Hughes is an Executive Assistant at Longitude Capital supporting both the Biotechnology and Medical Technology teams. Prior to joining Longitude Capital in 2007, Ms. Hughes was an Executive Assistant at Pequot Ventures. Previously, Ms. Hughes served as an Executive Assistant at Pollock Financial Group. Ms. Hughes holds a BA in Sociology from Menlo College.
—
Location: Menlo Park

Mr. Jonson is the Director of IT at Longitude Capital. Prior to joining Longitude Capital in 2023, Mr. Jonson worked for AllCovered, where he held roles as Senior Systems Engineer, Engineering Team Lead, and Senior Professional Services Engineer. Mr. Jonson has over 15 years of work experience at Managed IT Service Providers and several venture capital firms, where he managed and oversaw IT operations. Mr. Jonson holds a BS in Network Communications Management from DeVry University, Fremont.
—
Focus Areas: IT
Location: Menlo Park

Ms. Knopping is the VP of People at Longitude Capital. Prior to joining Longitude Capital in 2025, Ms. Knopping was the Head of Total Rewards and People Operations at GRAIL, a developer of blood cancer tests that was acquired by Illumina (ILMN) for $8 billion in 2021. During her tenure at GRAIL, Ms. Knopping collaborated with leadership to shape culture and drive strategies aligned with corporate objectives. Prior to GRAIL, Ms. Knopping was the Head of Total Rewards at Jazz Pharmaceuticals, a Longitude portfolio company, where she oversaw Total Rewards and People strategies as the company grew to over 1,300 employees and expanded globally. Ms. Knopping is a licensed CPA (inactive) and holds a BS in Accounting from the University of Illinois.
—
Focus Areas: Human Resources
Location: Menlo Park

Ms. Lok is the Vice President of Finance at Longitude Capital. Prior to joining Longitude Capital in 2015, Ms. Lok spent seven years at KPMG LLP (formerly Rothstein Kass) in audit and assurance, with a focus on life science venture capital funds. Ms. Lok holds a BA in Economics with an emphasis in Accounting from the University of California, Santa Barbara.
—
Location: Menlo Park

Ms. Oliveira is the Head of Legal as well as the Chief Compliance Officer at Longitude Capital. Prior to joining Longitude Capital in 2020, Ms. Oliveira was a Senior Associate at Weil, Gotshal & Manges LLP, where she counseled public and private companies, private equity firms, and venture funds in a wide range of matters, including mergers and acquisitions, securities law compliance, venture financings, and commercial arrangements. Ms. Oliveira graduated with highest honors from the University of California, Berkeley with a BA in Political Science and received a JD from the University of California, Berkeley, School of Law.
—
Focus Areas: Legal, Compliance
Location: Menlo Park

Ms. Shin is a Senior Tax Manager at Longitude Capital and a member of the Finance team. Prior to joining Longitude Capital in 2024, Ms. Shin was a Tax Manager at a16z. Prior to that, Ms. Shin held various tax-related roles at GI Partners, Pattern Energy Group, and PricewaterhouseCoopers LLP, with a focus on private equity and venture capital funds. Ms. Shin holds an MS in Taxation from Golden Gate University and a BA in Political Science from the University of California, Irvine.
—
Location: Menlo Park

Ms. Wright is an Executive Assistant at Longitude Capital. Prior to joining Longitude in 2018, Ms. Wright owned a Bar Method fitness studio. Previously, she worked in production at ABC News 20/20. Ms. Wright holds a BA in Communications from Fordham University.
—
Location: Boston